Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
Demonstrated or suggested benefit Inconclusive results Uncertain results Safety results
Immunostimulants drugs21

demonstrated 64 % decrease in hospitalization or death

demonstrated 3 % increase in viral clearance by day 7

inconclusive results for: death D28; deaths; hospitalization; mechanical ventilation; viral clearance ; viral clearance (time to event analysis only); emergent treatment-resistant variants; serious adverse events; adverse events

demonstrated 53 % decrease in Emergency room visit or hospitalization but the degree if certainty is unassessable

suggested 76 % decrease in clinical deterioration but the degree if certainty is unassessable

suggested 50 % increase in clinical improvement (time to event analysis only) but the degree if certainty is unassessable

suggested 50 % increase in Recovery (time to event analysis only) but the degree if certainty is unassessable

demonstrated 44 % decrease in symptomatic Covid-19 but the degree if certainty is unassessable

-
anti-inflammatory therapies2noneinconclusive results for: death D28; deaths; hospitalization or death; hospitalization; mechanical ventilation; recovery; related AE (TRAE); serious adverse events--
corticosteroids2noneinconclusive results for: death D28; deaths; hospitalization or death; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (7-day); hospitalization; recovery; adverse events--
inhaled corticosteroids2

demonstrated 21 % increase in clinical improvement

inconclusive results for: hospitalization or death; clinical improvement (14-day); mechanical ventilation; ICU admission

demonstrated 84 % decrease in clinical deterioration but the degree if certainty is unassessable

demonstrated 21 % increase in recovery but the degree if certainty is unassessable

-
Apilimod0- - - -
Immunosuppressants drugs0- - - -
Kinase inhibitors0- - - -
leflunomide0- - - -
meplazumab0- - - -
pirfenidone0- - - -
Polyinosinic-Polycytidylic Acid0- - - -
sargramostim0- - - -
statins0- - - -
thymosin0- - - -